GFAP and COVID-19: One study found that GFAP levels normalized in all COVID-19 patients despite disease severity and the persistence of reported cognitive symptoms suggesting that the symptoms of COVID-19-associated cognitive impairment linger without the presence of active CNS injury (Kanberg et al., 2021).